Benzinga

Benzinga

Benzinga

mercredi, août 19

Vir Biotechnology Inc

VIRNASDAQ
Trade with Public
Trade with Public
$9.77
0.282.95%
À la clôture: Aug 19, 5:00 PM EST
$9.89
0.121.19%
Après les heures: 6:58 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Vir Biotechnology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vir Biotechnology (VIR).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

9Buy
1Hold
Consensus RatingBuy# Analysts10Avg. Consensus PT$28Upside to Avg. PT+183.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 11, 2026Morgan StanleyMichelle GilsonPT RaiseOverweight$23→$27
Jun 3, 2026Leerink PartnersRoanna RuizPT RaiseOutperform$20→$21
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.
Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.
Benzinga Newsdesk

Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30

Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $26 to $30.
Benzinga Newsdesk

These Analysts Boost Their Forecasts On Vir Biotechnology

Avi Kapoor

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved